Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
99.755,29
-0,91%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Organon and Co (OGN) Organon and Co (OGN) Notizie

Organon and Co

OGN
15,74
-0,23 (-1,44%)
01 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/1/202513:30BWOrganon To Report Fourth Quarter and Full Year 2024 Results..
21/1/202513:01EDGAR2Form 8-K - Current report
23/12/202412:01EDGAR2Form 8-K - Current report
19/12/202413:30BWOrganon To Present at the 43rd Annual J.P. Morgan Healthcare..
16/12/202413:30BWFDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment..
06/12/202422:15EDGAR2Form 8-K - Current report
05/11/202413:40EDGAR2Form 8-K - Current report
05/11/202413:29BWUpdate on FDA Review of VTAMA® (tapinarof) Cream, 1% for the..
01/11/202413:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202413:40BW米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理
31/10/202413:39BW美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA)
31/10/202413:00EDGAR2Form 8-K - Current report
31/10/202412:30BWOrganon Reports Results for the Third Quarter Ended..
31/10/202405:02BWLa FDA des États-Unis accepte la demande de licence de..
30/10/202411:00BWUS FDA Accepts Biologics License Application (BLA) for..
29/10/202417:22BWOrganon conclut l'acquisition de Dermavant, qui propose..
28/10/202414:25BWOrganon Completes Acquisition of Dermavant, including..
09/10/202413:30BWOrganon to Report Third Quarter 2024 Results and Host..
08/10/202414:01PRNCAOrganon Canada promeut Geneviève Gauthier au poste de..
30/9/202421:26BWパージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成
30/9/202418:17BWPrimärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta®..
30/9/202417:59BWCritères principal atteint dans une étude clinique..
30/9/202412:00BWPrimary Endpoint Met in Phase 3 Comparative Clinical Study..
26/9/202415:50PRNCAOrganon Canada and the Alberta Women's Health Foundation..
26/9/202415:49PRNCAOrganon Canada et l'Alberta Women's Health Foundation..
23/9/202422:21EDGAR2Form 8-K - Current report
19/9/202420:30BWオルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得
19/9/202414:00BWOrganon erwirbt Dermavant und dessen innovative..
18/9/202413:30BWOrganon to Acquire Dermavant including its Innovative..
05/9/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202402:13BWオルガノンとリリーが片頭痛治療薬の商業化契約を拡大、11の新しい市場に参入
20/8/202423:06BWOrganon und Lilly erweitern Migräne-Vermarktungsvereinbarung..
20/8/202421:34BWOrganon y Lilly amplían su acuerdo de comercialización para..
20/8/202416:20BWOrganon et Lilly élargissent l'accord de commercialisation..
20/8/202413:30BWOrganon & Lilly Expand Migraine Commercialization Agreement..
07/8/202414:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202413:39EDGAR2Form 8-K - Current report
06/8/202413:30BWOrganon Reports Results for the Second Quarter Ended June..
06/8/202411:49IHMARKETNEWSUS Index Futures Rise After Market Sell-off, Oil Prices Trim..
09/7/202413:30BWOrganon To Report Second Quarter 2024 Results and Host..
11/6/202421:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202421:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202421:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202413:00EDGAR2Form 8-K - Current report
24/5/202419:59BWEuropäische Arzneimittel-Agentur (EMA) validiert..
Apertura: 15,90 Min: 15,56 Max: 15,93
Chiusura: 15,97

La tua Cronologia

NYSE
OGN
Organon
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci